Literature DB >> 19012065

Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up.

H Deda1, M C Inci, A E Kürekçi, A Sav, K Kayihan, E Ozgün, G E Ustünsoy, S Kocabay.   

Abstract

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive loss of spinal cord and cortical motoneurons. Despite improved understanding of the mechanisms underlying ALS, in clinical practice the management of ALS remains essentially supportive and focused on symptom relief. However, over the past few years stem cell research has expanded greatly as a tool for developing potential new therapies for treating incurable neurodegenerative diseases.
METHODS: Thirteen patients with sporadic amyotrophic lateral sclerosis (SALS) were included in this study, and bone marrow (BM)-derived hematopoietic progenitor stem cells were used. We selected patients with bulbar involvement and severe loss of movement. Our aim was to put the stem cells into the end of the brain stem and at the beginning of the spinal cord because the blood-brain barrier is intact in ALS and this region was the most affected part in our patients. Under general anesthesia, a total laminectomy was performed at the C1-C2 level. Stem cells were injected to the anterior part of the spinal cord.
RESULTS: During the follow-up of 1 year after stem cell implantation, nine patients became much better compared with their pre-operative status, confirmed by electro neuro myography (ENMG). One patient was stable without any decline or improvement in his status. Three patients died 1.5, 2 and 9 months, respectively, after stem cell therapy as a result of lung infection and myocardial infarction (MI). DISCUSSION: These results show that stem cell therapy is a safe, effective and promising treatment for ALS patients.

Entities:  

Mesh:

Year:  2009        PMID: 19012065     DOI: 10.1080/14653240802549470

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  42 in total

1.  Human embryonic stem cell-derived mesenchymal stromal cells.

Authors:  Peiman Hematti
Journal:  Transfusion       Date:  2011-11       Impact factor: 3.157

Review 2.  Intraspinal stem cell transplantation for amyotrophic lateral sclerosis.

Authors:  Kevin S Chen; Stacey A Sakowski; Eva L Feldman
Journal:  Ann Neurol       Date:  2016-02-12       Impact factor: 10.422

Review 3.  Regenerative therapy for neuronal diseases with transplantation of somatic stem cells.

Authors:  Hiroshi Kanno
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

4.  Cell Therapy From Bench to Bedside Translation in CNS Neurorestoratology Era.

Authors:  Hongyun Huang; Lin Chen; Paul Sanberg
Journal:  Cell Med       Date:  2010-01-01

5.  Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.

Authors:  S Fadilah Abdul Wahid; Zhe Kang Law; Nor Azimah Ismail; Nai Ming Lai
Journal:  Cochrane Database Syst Rev       Date:  2019-12-19

6.  The effect of autologous bone marrow mononuclear cell transplantation on the survival duration in Amyotrophic Lateral Sclerosis - a retrospective controlled study.

Authors:  Alok K Sharma; Hemangi M Sane; Amruta A Paranjape; Nandini Gokulchandran; Anjana Nagrajan; Myola D'sa; Prerna B Badhe
Journal:  Am J Stem Cells       Date:  2015-03-15

Review 7.  Omental transplantation for neurodegenerative diseases.

Authors:  Hernando Rafael
Journal:  Am J Neurodegener Dis       Date:  2014-09-06

8.  Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages.

Authors:  Jaehyup Kim; Peiman Hematti
Journal:  Exp Hematol       Date:  2009-09-20       Impact factor: 3.084

Review 9.  Stem cells in human neurodegenerative disorders--time for clinical translation?

Authors:  Olle Lindvall; Zaal Kokaia
Journal:  J Clin Invest       Date:  2010-01       Impact factor: 14.808

10.  Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

Authors:  Alexandre Henriques; Claudia Pitzer; Armin Schneider
Journal:  Front Neurosci       Date:  2010-06-11       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.